For the discovery of drugs that inhibit macrophage activation for use in severe cases of COVID-19. These drugs may suppress cytokine storm, hyperinflammation, and pulmonary infiltration to prevent respiratory failure.
- Funded by Emergent Ventures Fast Grants
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Funder
Emergent Ventures Fast GrantsPrincipal Investigator
Dr. Kipp WeiskopfResearch Location
United States of AmericaLead Research Institution
Whitehead Institute for Biomedical ResearchResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable